What Futurelife does

FutureLife is a Prague-headquartered, privately held pan-European reproductive medicine and genetics group operating 62 fertility clinics across 16 countries with a clinical team of roughly 3,000 specialists. Founded in 1991, the network has facilitated 188,712 births to date (approximately one every 36 minutes) and now conducts over 77,000 IVF cycles annually. The company's core service portfolio spans IUI, IVF, donor programmes, and fertility preservation (egg freezing), supplemented by three specialized sub-brands: GNTlabs by GENNET (an advanced genetic laboratory offering molecular genetics, cytogenetics, preimplantation genetic testing, and bioinformatics), the FutureLife Gamete Bank (a donor egg bank with stringent screening), and Serpha (an online fertility medication pharmacy).

The underlying technology stack combines established clinical IVF laboratory capabilities with a network-wide AI platform deployed in 2026 through a partnership with Alife Health. The platform includes three CE-marked clinical decision support tools — Embryo Predict (blastocyst evaluation), Success Predictor (treatment outcome forecasting), and Egg Retrieval Report (procedure optimization) — making FutureLife the first large-scale European fertility network to institutionalize multi-tool AI across its clinics. Patient access is facilitated through owned clinic locations, a mobile app available on iOS and Android, and the Serpha e-commerce pharmacy.

FutureLife is jointly owned by private equity firms CVC Capital Partners and Hartenberg Holding (the latter owned by Czech billionaire and former Prime Minister Andrej Babiš). The business model is B2C and quote-based per treatment cycle: pricing is not publicly disclosed and varies by treatment type, medication regimen, donor requirements, and clinic location, producing high-touch, multi-year patient journeys with sticky repeat-customer economics. The company has executed a sustained acquisition-led expansion since 2022, absorbing The Centre for Reproductive & Genetic Health, Institut Marquès, BCRM, Bahceci Health Group, and Herts & Essex Fertility Centre across the UK, Spain, and Turkey, positioning the group as a pan-European roll-up platform in a highly fragmented fertility services market.

Name

Futurelife

Legal name

FutureLife

Website

https://futurelife.cz

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

FutureLife is a Prague-headquartered pan-European fertility and reproductive medicine group operating 62 clinics across 16 countries, providing IVF, IUI, donor programmes, and fertility preservation services to individuals and couples, supplemented by genetic laboratory, gamete bank, and online pharmacy sub-brands.

Ownership category

akta.pro rank

Product category

Reproductive Medicine

NAICS

Family Planning Centers (621410), Family Planning Centers (62141)

SIC

Services-Hospitals (8060)

akta.pro primary industry

Fertility, Reproductive Endocrinology & IVF Centers (HLAFAJAD)

akta.pro secondary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Fertility treatments
• Reproductive medicine
• IVF services
• Genetic testing
• Fertility preservation

Headquarters

HQ city

Prague

HQ country

Czechia

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Fertility Treatment Services: FutureLife generates revenue through providing fertility treatments including IUI, IVF, donor programmes, and fertility preservation services across their network of 60+ clinics in 16 European countries. Treatment cycles are the primary revenue driver, with over 77,000 IVF cycles conducted annually.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

FutureLife operates a pan-European fertility and reproductive medicine network of 60+ clinics across 16 countries, providing IUI, IVF, donor programmes, and fertility preservation services. Core offerings are supported by the FutureLife Gamete Bank (donor eggs), GNTlabs by GENNET (genetic testing including PGT, molecular genetics, cytogenetics, bioinformatics), and Serpha online pharmacy for fertility medications. The company conducts over 77,000 IVF cycles annually and has facilitated over 188,712 births since 1991.

Product overview

FutureLife is a pan-European fertility and reproductive medicine network offering a comprehensive suite of services across 60+ clinics in 16 countries. The core offerings include IUI, IVF, donor programmes, and fertility preservation (egg freezing). These are supported by the FutureLife Gamete Bank for donor eggs, GNTlabs by GENNET for advanced genetic laboratory services (molecular genetics, cytogenetics, PGT, bioinformatics), and Serpha online pharmacy for fertility medications. The company conducts over 77,000 IVF cycles annually and has facilitated over 188,000 births since 1991. A 2026 network-wide AI platform partnership with Alife Health deploys predictive analytics tools (Embryo Predict™, Success Predictor™) and clinical decision support (Egg Retrieval Report) across the clinic network.

Differentiator

Problem solved

Functional benefit

Brands

• GNTlabs by GENNET: One of Europe's most advanced genetic laboratories specializing in molecular genetics, cytogenetics, PGT, and bioinformatics.
• Serpha

Products and services

• Intrauterine Insemination (IUI) Fertility treatment involving placement of sperm directly inside the womb around ovulation time, performed in natural or medicated cycles. A less invasive fertility treatment offered across FutureLife's clinic network.
• In Vitro Fertilization (IVF) Highly effective fertility treatment using fertility hormones to stimulate egg production, followed by egg collection and laboratory combination with sperm to create embryos. The company's primary revenue driver, with over 77,000 IVF cycles conducted annually across the network.
• Donor Programme Treatment pathway utilizing donated eggs or sperm to help individuals and couples create families through assisted reproduction, supported by the FutureLife Gamete Bank donor egg supply.
• Fertility Preservation (Egg Freezing) Oocyte cryopreservation service allowing women to preserve fertility by freezing and storing eggs for future use, suitable for personal, social, or medical reasons including prior to medical treatments that may affect fertility.
• FutureLife Gamete Bank Europe's leading assisted reproductive technology donor egg bank offering thorough donor screening, skilled doctors, and a caring approach to maximize chances of treatment success for patients requiring donor gametes.
• GNTlabs by GENNET One of Europe's most advanced genetic laboratories specializing in molecular genetics, cytogenetics, preimplantation genetic testing (PGT), and bioinformatics, as well as embryology and immunology. Offers genetic screenings, carrier tests, and diagnostic tests for genetic disorders to support fertility treatment decisions.
• Serpha Online pharmacy specializing in fertility medication, supporting patients throughout their fertility treatment journey. Accessible via www.serpha.eu.

Quantifiable outcome

• 188,712 babies delivered since 1991 (one every 36 minutes)
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

One partnership is on record.

• Alife HealthcoreTechnology or Integration · 5 May 2026FutureLife Group announced a network-wide partnership with Alife Health to deploy a comprehensive AI platform for fertility care across its 60 clinics spanning 16 European countries. The deployment includes Embryo Predict™ (CE-marked AI tool for blastocyst evaluation), Success Predictor™, and Egg Retrieval Report tools, following a successful multi-clinic pilot program. This makes FutureLife the first large-scale European fertility network to adopt a multi-tool AI platform, aiming to standardize reporting, improve clinical consistency, and extend data-driven patient support throughout the IVF journey.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• TFP (The Fertility Partnership): UK-based fertility clinic network offering IVF, IUI, donor, and genetic services across multiple sites. Direct competitor to FutureLife's UK operations (BCRM, Herts & Essex, CRGH) with similar service mix and patient segment.
• Ginemed: Spanish fertility clinic network offering IVF, donor programmes, and genetic services with a strong Iberian presence. Directly comparable to FutureLife's Institut Marquès subsidiary and overlapping patient segments.
• CARE Fertility: UK fertility clinic group offering full-service IVF, donor, and genetic testing services. Direct competitor to FutureLife's UK clinics, with overlapping patient demographics and similar clinical offerings.
• Boston IVF: US fertility clinic network with international expansion ambitions, offering IVF, donor, and genetic services. Comparable to FutureLife in multi-clinic fertility network model and PE-backed growth trajectory.
• CREATE Fertility: UK-based fertility network specializing in mild/mild-stim IVF and natural-cycle approaches. Comparable to FutureLife in clinic-network structure and core IVF/IUI offerings, particularly relevant overlap in the UK market.
• Medicover: Sweden-based healthcare services provider with significant fertility clinic operations across Central and Eastern Europe. Comparable to FutureLife in geographic footprint across CEE and similar clinic-based reproductive service model.
• GeneraLife (IVI-RMA): Europe's largest fertility network operating across Spain, Italy, and other markets with similar IVF, IUI, donor, and genetic services. Closest direct competitor to FutureLife in pan-European fertility clinic scale and PE-backed consolidation model (KKR-backed).
• CCRM (Colorado Center for Reproductive Medicine): US-based fertility network known for advanced reproductive technology and high success rates, with own genetic lab. Comparable to FutureLife's vertical integration including GNTlabs and strong IVF success-rate positioning.
• Eugin (Fresenius Helios): Part of Fresenius Helios hospital group, Eugin operates fertility clinics across Southern Europe (Spain, Italy, Portugal, Germany). Comparable to FutureLife in clinic-based IVF services and donor programmes, with the added advantage of hospital-system affiliation.

Broad incumbents

• Virtus Health: Australia-headquartered fertility and diagnostics network with international operations across multiple countries. Comparable to FutureLife in pan-regional fertility network scale and clinic-based service delivery model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/futurelife-a-s

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Futurelife